TomoTherapy and Hitachi Medical Corporation Sign Letter of Intent for Hi∙Art® System Distribution in Japan
TomoTherapy Incorporated (NASDAQ:TOMO) announced today that it has signed a letter of intent with Hitachi Medical Corporation (HMC) to distribute the Hi·Art® cancer treatment system in Japan.
MADISON, Wis. (PRWEB) October 16, 2008
"We are proud to be in discussions with Hitachi Medical Corporation, a highly-respected Japanese company with an excellent national service infrastructure," said TomoTherapy CEO Fred Robertson, M. D. "HMC should prove to be an ideal partner for TomoTherapy, and for our valued Japanese customers."
Terms of the agreement between TomoTherapy and HMC are being finalized. Details will be announced upon contract signing. The partnership between TomoTherapy and Hitachi Medical Corporation is expected to commence by the end of 2008.
About Hitachi Medical Corporation
Hitachi Medical Corporation is a full-line supplier of medical equipment in Japan and a subsidiary of Hitachi, Ltd., which is a global electronics company with more than US$100 billion of sales in consolidated basis and about 390,000 employees worldwide.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy. com.
©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.
